Cerus (CERS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Apr, 2026Executive summary
Annual meeting scheduled for June 2, 2026, with virtual participation and voting options for shareholders.
Key business highlights include $206.1M in 2025 product revenue, positive adjusted EBITDA, and new regulatory approvals.
Leadership transition planned: Vivek Jayaraman to become President and CEO on July 1, 2026; William Greenman to serve as Executive Chairman.
Board and management emphasize strong corporate governance, risk oversight, and stakeholder engagement.
Voting matters and shareholder proposals
Election of two directors (William M. Greenman and Ann Lucena) for terms expiring at the 2029 annual meeting.
Approval of an amendment to the 2024 Equity Incentive Plan, increasing authorized shares by 10 million.
Advisory vote on executive compensation (say-on-pay).
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.
Board of directors and corporate governance
Board consists of seven members, six of whom are independent; diverse in tenure, age, gender, and ethnicity.
Board refreshment ongoing, with significant changes since 2018 to enhance expertise.
Lead Independent Director role established to balance combined CEO/Chair position.
Annual board and committee self-assessments and skills gap analyses conducted.
Stock ownership guidelines in place for directors and CEO.
Latest events from Cerus
- Q3 2024 product revenue up 16%, net loss narrowed, and full-year guidance raised.CERS
Q3 20248 Jul 2026 - 2025 revenue rose 16% with narrowing losses and surging INTERCEPT Fibrinogen Complex demand.CERS
Q4 20258 Jul 2026 - Q2 revenue up 16%, net loss narrowed, and 2024 guidance raised on strong North American growth.CERS
Q2 20248 Jul 2026 - BARDA awards up to $248M for U.S. program; Europe plans new submission after CE Mark setback.CERS
Study Update8 Jul 2026 - All proposals passed, including director elections and plan amendments, with no shareholder questions.CERS
AGM 20264 Jun 2026 - Q1 2026 revenue up 23%, product revenue up 24%, and net loss narrowed to $1.6 million.CERS
Q1 20263 May 2026 - Record revenue growth and global expansion driven by INTERCEPT blood safety technologies.CERS
Corporate presentation22 Apr 2026 - Virtual vote set for June 2026 on directors, equity plan, pay, and auditor ratification.CERS
Proxy filing22 Apr 2026 - Record 2025 growth and global expansion highlight strong momentum in blood safety innovation.CERS
Corporate presentation9 Mar 2026